We focused on immune cell markers (CD3, CD4, CD8, CD20) as lymphocytes are relatively regular in size and shape and we did not include CD16 and K17 in this evaluation since the myeloid and tumor cells are irregular in size and shape. The gene discussed is KRT17; the disease is neoplasm.